Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
RESEARCH TOOLSreports
Ultragenyx Pharmaceutical (RARE) Stock Price & Analysis
635 Followers
RARE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$31.52 - $54.98
Previous Close$41.87
Volume732.22K
Average Volume (3M)733.91K
Market Cap
$3.48B
Enterprise Value$2.90B
Total Cash (Recent Filing)$577.21M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-5.2
Beta0.87
Next Earnings
Aug 01, 2024EPS Estimate
-$1.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.03
Shares Outstanding83,133,341
10 Day Avg. Volume734,190
30 Day Avg. Volume733,907
Standard Deviation0.14
R-Squared0.06
Alpha-0.00450
Financial Highlights & Ratios
Price to Book (P/B)53.77
Price to Sales (P/S)27.32
Price to Cash Flow (P/CF)-10.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.80
Enterprise Value/Gross Profit6.69
Enterprise Value/Ebitda-9.13
Forecast
1Y Price Target
$92.15Price Target Upside121.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Ultragenyx Pharmaceutical News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsUpdates for IONS582 for Angelman Syndrome show the majority of patients improving, with detailed results expected to be shared soon, indicating potential efficacy and advancement in treatment.
Drug SafetyION582 has a favorable safety profile, aligning with patient medical histories and the nature of the treatment administration, suggesting a reliable option for Angelman Syndrome therapy.
Market CompetitionAnalyst maintains a BUY rating for RARE, citing the valuation disconnect and the probability-adjusted value of their competitive pipeline, which includes promising therapies like GTX-102.
Bears Say
Financial PerformanceCommercial sales for the quarter were a touch below consensus estimates.
Licensing And Clinical ProfileBiogen has elected NOT to exercise its option to license the product (ION582), which may call into question the emerging clinical profile.
Safety And Adverse EventsSafety concerns have re-emerged with the occurrence of serious adverse events of radiculopathy in recent cohorts.
---
Ownership Overview
9.84% Insiders
34.18% Mutual Funds
54.34% Other Institutional Investors
1.64% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RARE FAQ
What was Ultragenyx Pharmaceutical’s price range in the past 12 months?
Ultragenyx Pharmaceutical lowest stock price was $31.52 and its highest was $54.98 in the past 12 months.
What is Ultragenyx Pharmaceutical’s market cap?
Currently, no data Available
When is Ultragenyx Pharmaceutical’s upcoming earnings report date?
Ultragenyx Pharmaceutical’s upcoming earnings report date is Aug 01, 2024 which is in 72 days.
How were Ultragenyx Pharmaceutical’s earnings last quarter?
Ultragenyx Pharmaceutical released its earnings results on May 02, 2024. The company reported -$2.03 earnings per share for the quarter, missing the consensus estimate of -$1.747 by -$0.283.
Is Ultragenyx Pharmaceutical overvalued?
According to Wall Street analysts Ultragenyx Pharmaceutical’s price is currently Undervalued.
Does Ultragenyx Pharmaceutical pay dividends?
Ultragenyx Pharmaceutical does not currently pay dividends.
What is Ultragenyx Pharmaceutical’s EPS estimate?
Ultragenyx Pharmaceutical’s EPS estimate is -$1.68.
How many shares outstanding does Ultragenyx Pharmaceutical have?
Ultragenyx Pharmaceutical has 83,133,340 shares outstanding.
What happened to Ultragenyx Pharmaceutical’s price movement after its last earnings report?
Ultragenyx Pharmaceutical reported an EPS of -$2.03 in its last earnings report, missing expectations of -$1.747. Following the earnings report the stock price went down -1.042%.
Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical?
Among the largest hedge funds holding Ultragenyx Pharmaceutical’s share is Sands Capital Management LLC. It holds Ultragenyx Pharmaceutical’s shares valued at 180M.
---
Ultragenyx Pharmaceutical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$92.15 (121.89% Upside)
$92.15 (121.89% Upside)
Blogger Sentiment
Neutral
RARE Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 109.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.81%
12-Months-Change
Fundamentals
Return on Equity
-340.05%
Trailing 12-Months
Asset Growth
-5.52%
Trailing 12-Months
Company Description
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.
---
RARE Company Deck
---
RARE Earnings Call
Q1 2024
0:00 / 0:00
---
RARE Stock 12 Month Forecast
Average Price Target
$92.15
▲(121.89% Upside)
Technical Analysis
Best Analysts Covering RARE
1 Year
1 Year Success Rate
9/17 ratings generated profit
1 Year Average Return
+0.03%
reiterated a buy rating last month
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 52.94% of your transactions generating a profit, with an average return of +0.03% per trade.
---